Quick Facts / Company Snapshot
- Official Name: Eckert & Ziegler SE
- Headquarters: Berlin, Germany (Robert-Rössle-Str. 10, 13125 Berlin)
- Founded: 30+ year history
- Total Revenue (2024): €295.8 million
- Revenue Growth (YoY): 20.2%
- EBITDA (2024): €73.9 million
- EBIT (2024): €59.9 million
- Adjusted EBIT (2024): €65.9 million
- Net Profit (2024): €33.3 million
- Earnings Per Share (Undiluted): €1.60
- Dividend Proposal (2024): €0.50 per share
- Total Assets: €442.4 million
- Equity Ratio: 50%
- Employees (Annual Average): 1,091
- R&D Expenditure (Continuing Operations): €4.8 million
- Key Growth Segment: Medical Segment (+29% Revenue)
- Primary Sales Region: North America (€115.6 million)
- Legal Form Change: Converted to Societas Europaea (SE) in March 2024
- Strategic Spin-off: Pentixapharm AG spun off in October 2024
Company Overview
Eckert & Ziegler SE is a globally active provider of isotope technology components used in medical, scientific, and industrial applications. The company operates as a management holding company with specialized subsidiaries worldwide that process radioisotopes and develop, manufacture, and sell isotope technology components, medical technology equipment, and related products. The group’s core competencies lie in handling and processing radioactive materials in specially equipped production facilities located in Europe, the United States, South America, and Asia.
The business model is centered on serving radiation therapists, radiation oncologists, nuclear medicine specialists, and industrial partners. Eckert & Ziegler positions itself as a critical supplier of precursors to pharmaceutical companies that manufacture and sell radiopharmaceuticals. The company’s mission is explicitly defined as “Contributing to saving lives.”
In the 2024 financial year, the group achieved record revenue levels, driven significantly by the demand for radiopharmaceutical products. The company operates in a market characterized by high entry barriers due to strict licensing requirements, complex regulatory landscapes, and the need for specialized infrastructure. Eckert & Ziegler manages its operating business through two primary segments—Medical and Isotope Products—supported by a holding segment that provides central services.
Business Segments
The operational activities of Eckert & Ziegler SE are divided into two main strategic segments: Medical and Isotope Products. A third segment, “Other,” encompasses the holding company functions.
Medical Segment
The Medical segment is the primary growth driver for the group, focusing on products and services for nuclear medicine and radiation therapy. This segment targets pharmaceutical companies, hospitals, and medical research institutions.
- Segment Revenue (External): €148.4 million
- Percentage of Total Revenue: 50.2%
- Total Segment Revenue (including internal): €148.7 million
- Adjusted EBIT: €39.7 million
Operational Scope:
The Medical segment specializes in longer-lived radioisotopes for pharmaceutical applications, early-development services, and equipment. A significant portion of revenue is derived from pharmaceutical-grade radioactive substances that serve diagnostic or therapeutic functions within drugs. Key product lines include the GalliaPharm® radionuclide generator and therapeutic isotopes such as Yttrium-90 and Lutetium-177.
This segment also acts as a Contract Manufacturing Organization (CMO), offering radiopharmaceutical services under Good Manufacturing Practice (GMP) conditions. These services range from process development and scale-up to the manufacturing of clinical batches (Phase I, II, III) and commercial supply. The segment also includes a plant engineering division that supports international drug developers with hot cell solutions, laboratory equipment, and automated radiosynthesis systems.
Isotope Products Segment
The Isotope Products segment focuses on industrial and scientific applications, as well as specific medical imaging components. It serves a diverse customer base including equipment manufacturers and scientific institutes.
- Segment Revenue (External): €147.5 million
- Percentage of Total Revenue: 49.8%
- Total Segment Revenue (including internal): €158.0 million
- Adjusted EBIT: €31.0 million
Operational Scope:
This segment manufactures and distributes radiation sources and standards used for imaging techniques, scientific calibration, quality assurance, and industrial measurement. It maintains a strong market position in flood sources for the calibration of gamma cameras.
Beyond manufacturing, the Isotope Products segment provides comprehensive life-cycle services. These include the repossession of used radiation sources, acceptance of low-level radioactive waste, conditioning and recycling of isotope materials, and transportation logistics. The segment also comprises the business with Technetium-99m generators and related biomolecules (SPECT diagnostics), managed primarily through subsidiaries in South America.
Other Segment
The Other segment primarily represents the activities of the holding company, Eckert & Ziegler SE.
- Segment Revenue (External): €0 million
- Percentage of Total Revenue: 0.0%
- Adjusted EBIT: -€4.8 million
Operational Scope:
This segment pools central group services such as Legal, Controlling, Accounting, IT, Human Resources, and Radiation Protection. The holding company finances itself through service fees charged to subsidiaries, interest income from loans provided to group companies, and profit distributions. Until October 2024, this segment also included the “Clinical Assets” division (Pentixapharm AG), which was subsequently spun off.
History and Evolution
Eckert & Ziegler has a corporate history spanning over 30 years. The financial year 2024 marked several historic milestones and structural changes that reshaped the corporate profile.
Conversion to Societas Europaea (SE)
On March 19, 2024, the company successfully completed its change of legal form from a German stock corporation (AG) to a European stock corporation (Societas Europaea). Following this conversion, the company trades under the name Eckert & Ziegler SE.
Spin-off of Pentixapharm AG
A significant strategic move in 2024 was the separation of the clinical assets division. In October 2023, the Executive and Supervisory Boards decided to dispose of the group’s clinical drug development activities to focus resources on the core isotope business. This culminated in the spin-off of Pentixapharm AG (including its subsidiary Myelo Therapeutics GmbH). The spin-off became legally effective on October 2, 2024, with shareholders receiving one share in the newly formed Pentixapharm Holding AG for each share held in Eckert & Ziegler SE.
Actinium-225 Production Launch
In December 2024, Eckert & Ziegler successfully commissioned a production facility for Actinium-225 (Ac-225). This project, executed in collaboration with the Nuclear Physics Institute of the Czech Academy of Sciences (UJF), utilizes a cyclotron-based method to produce this highly sought-after alpha-emitter. This marked a technological breakthrough for the company, establishing a scalable source for therapeutic isotopes.
Record Financial Performance
The 2024 fiscal year was the most successful in the company’s history, achieving record revenue of €295.8 million and a 27% increase in net profit. This performance underscored the successful strategic pivot towards the radiopharmaceutical manufacturing sector.
Products and Services
Eckert & Ziegler offers a wide array of products categorized by their application in medical, scientific, and industrial fields.
Radiopharmaceuticals and Isotopes
- Revenue Contribution: Significant portion of Medical Segment (€148.4 million).
- Primary Products:
- GalliaPharm® (Ge-68/Ga-68 Generator): A radionuclide generator used to label carrier molecules for diagnostic PET imaging. In 2024, the availability of GalliaPharm® was expanded, receiving EU approval which opens access to 14 additional countries in the European Economic Area.
- Lutetium-177 (Lu-177): A beta-emitter used for targeted radionuclide therapy. In 2024, Eckert & Ziegler received European Commission approval for “Theralugand,” its precursor Lu-177 product.
- Yttrium-90 (Y-90): Used for the production of radioactive embolization devices for liver tumor treatment.
- Actinium-225 (Ac-225): An alpha-emitter for targeted cancer therapy. Production commenced in late 2024.
Brachytherapy Products
- Revenue Contribution: Included in Medical Segment.
- Primary Products:
- Tumor Seeds: Small implants containing Iodine-125 used for the treatment of prostate cancer.
- Ophthalmic Applicators: Products based on Ruthenium-106 or Iodine-125 designed for the treatment of uveal melanoma (eye cancer).
Medical Equipment and Plant Engineering
- Revenue Contribution: €20.4 million (Revenue from construction contracts).
- Primary Products:
- Hot Cells: Shielded enclosures for handling radioactive materials.
- Modular-Lab Systems: Automated radiosynthesis equipment for the production of radiopharmaceuticals.
- Quality Control Equipment: Devices for analyzing radiopharmaceutical products.
Isotope Products (Industrial & Scientific)
- Revenue Contribution: €147.5 million (Isotope Products Segment).
- Primary Products:
- Calibration Standards: Radioactive sources used to calibrate measurement instruments in science and industry.
- Flood Sources: Large-area sources used for the quality control and calibration of gamma cameras in hospitals.
- Industrial Sources: Components used in measurement gauges for applications such as oil exploration and density measurement.
- Technetium-99m Generators: Generators for SPECT diagnostic imaging, primarily distributed in Latin America.
Services
- Revenue Contribution: €37.5 million (Total Group Services Revenue).
- Primary Services:
- Waste Disposal: Taking back used sources and processing low-level radioactive waste.
- Contract Manufacturing (CMO): GMP-compliant development and manufacturing of radiopharmaceuticals for third parties.
- Logistics: Specialized transport of hazardous radioactive materials.
Brand Portfolio
Eckert & Ziegler manages several product brands that are well-established in the nuclear medicine and industrial sectors.
GalliaPharm®
- Scope: Germanium-68/Gallium-68 radionuclide generators.
- Status: A leading product for PET diagnostics. In 2024, regulatory approval was expanded to the entire European Economic Area, and an approval application was submitted to the Japanese health authority.
Theralugand®
- Scope: Pharmaceutical-grade Lutetium-177 (n.c.a.) precursor.
- Status: Received approval from the European Commission in 2024, enabling its use in routine clinical applications across the EU.
Modular-Lab
- Scope: Automated synthesis modules for radiopharmaceutical production.
- Status: A versatile platform used globally for research and routine production of tracers.
Eckert & Ziegler BEBIG
- Scope: Heritage brand for brachytherapy products (seeds and applicators).
- Status: Continues to represent high-quality implants for cancer treatment.
Geographical Presence
Eckert & Ziegler maintains a global footprint with production, sales, and administrative facilities distributed across key markets.
North America
- Revenue (2024): €115.6 million
- Percentage of Total Revenue: 39.1%
- Key Locations:
- Wilmington, Massachusetts: Production site for radiopharmaceuticals and bulk isotopes (Y-90).
- Valencia, California: Headquarters for Isotope Products, manufacturing of radiation sources.
- Atlanta, Georgia: Facility for analytics and standards (Eckert & Ziegler Analytics Inc.).
- Hopkinton, Massachusetts: Radiopharma operations.
Europe
- Revenue (2024): €107.1 million
- Percentage of Total Revenue: 36.2%
- Key Locations:
- Berlin, Germany: Corporate headquarters, production of medical devices, and radiopharma operations.
- Braunschweig, Germany: Site for Isotope Products and environmental services.
- Dresden, Germany: Center for plant engineering and equipment manufacturing.
- Prague, Czech Republic: Production of Actinium-225 and other isotopes.
- Leipzig, Germany: Environmental services and recycling.
Asia/Pacific
- Revenue (2024): €40.1 million
- Percentage of Total Revenue: 13.6%
- Key Locations:
- Jintan (Changzhou), China: New production facility completed in 2024; planned radiopharmaceutical production from 2027.
Other Regions (South America, Middle East, Africa)
- Revenue (2024): €33.0 million
- Percentage of Total Revenue: 11.1%
- Key Locations:
- Buenos Aires, Argentina: Production of Tc-99m generators (Tecnonuclear S.A.).
- São Paulo, Brazil: Sales and distribution hub.
Financial Performance Analysis
The financial year 2024 was characterized by record-breaking performance across key metrics. The group significantly improved its profitability and cash flow generation while maintaining a robust balance sheet.
Profit and Loss Analysis
- Total Revenue: Increased by 20% to €295.8 million (2023: €246.1 million). This growth was driven by a 29% increase in the Medical segment and a 13% increase in the Isotope Products segment.
- Gross Profit: Rose to €143.2 million, resulting in a gross margin improvement.
- EBITDA: Increased by 26% to €73.9 million (2023: €58.8 million).
- EBIT: Grew by 32% to €59.9 million (2023: €45.5 million). The EBIT margin improved to 20% (2023: 18%).
- Adjusted EBIT: Reached €65.9 million, excluding special items such as hyperinflation effects and impairment losses.
- Net Profit (After Minorities): Increased by 27% to €33.3 million (2023: €26.3 million).
- Earnings Per Share: Rose to €1.60 (2023: €1.26).
- Expenses:
- Sales & Distribution: €28.1 million.
- General & Administrative: €45.5 million.
- R&D (Continuing Operations): €4.8 million.
P&L Summary Table:
| Metric | 2024 (€ millions) | 2023 (€ millions) | Change |
| Revenue | 295.8 | 246.1 | +20% |
| Cost of Sales | -152.7 | -132.7 | +15% |
| Gross Profit | 143.2 | 113.4 | +26% |
| EBITDA | 73.9 | 58.8 | +26% |
| EBIT | 59.9 | 45.5 | +32% |
| Net Profit (Shareholders) | 33.3 | 26.3 | +27% |
Balance Sheet Analysis
- Total Assets: Increased slightly to €442.4 million (2023: €439.4 million).
- Equity: Remained stable at €223.4 million despite the spin-off of Pentixapharm, which reduced equity reserves.
- Equity Ratio: 50% (2023: 51%), indicating a very solid capital structure.
- Liquidity: Cash and cash equivalents increased significantly by 74% to €118.2 million (2023: €68.0 million).
- Net Financial Position: Improved to €98.0 million (2023: €41.6 million), calculated as liquidity plus securities minus financial liabilities.
- Liabilities: Non-current liabilities increased to €145.0 million, primarily due to higher provisions for site restoration.
Balance Sheet Summary Table:
| Metric | 2024 (€ millions) | 2023 (€ millions) |
| Non-Current Assets | 217.0 | 205.7 |
| Current Assets | 225.4 | 233.7 |
| Total Assets | 442.4 | 439.4 |
| Equity | 225.2 | 224.1 |
| Non-Current Liabilities | 145.0 | 131.6 |
| Current Liabilities | 72.2 | 83.7 |
| Total Equity & Liabilities | 442.4 | 439.4 |
Cash Flow Analysis
- Operating Cash Flow: Surged by 86% to €84.0 million (2023: €45.2 million). This was driven by the strong operating result and improvements in working capital management.
- Investing Cash Flow: Cash outflow of €16.6 million (2023: outflow of €42.7 million). Investments were focused on expanding the Dresden site and Ac-225 production facilities.
- Financing Cash Flow: Cash outflow of €10.0 million (2023: outflow of €9.3 million). Included loan repayments and dividend distributions.
- Free Cash Flow: Strongly positive due to high operating cash flow and moderate capex.
Cash Flow Summary Table:
| Metric | 2024 (€ millions) | 2023 (€ millions) |
| Operating Cash Flow | 84.0 | 45.2 |
| Investing Cash Flow | -16.6 | -42.7 |
| Financing Cash Flow | -10.0 | -9.3 |
| Change in Cash | +40.5 | -14.7 |
Board of Directors and Leadership Team
Executive Board (Vorstand)
- Dr. Harald Hasselmann:
- Role: Chairman of the Executive Board (CEO) & Medical Segment.
- Profile: Holds a doctorate in economics. Experienced in international pharmaceutical companies. Joined Eckert & Ziegler in 2015 as Managing Director of BEBIG GmbH; appointed to the Executive Board in 2017; CEO since June 2023. Responsible for strategy, finance, and the Medical segment.
- Frank Yeager:
- Role: Member of the Executive Board (Isotope Products Segment).
- Profile: Holds an MBA and mechanical engineering degree. Joined the US subsidiary in 2001. Appointed to the Executive Board in 2023. Responsible for the global industrial and scientific isotope business.
- Dr. Gunnar Mann:
- Role: Member of the Executive Board (since Jan 1, 2025).
- Profile: Holds a doctorate in physics. Joined the company in 1998. Previously head of development and managing director of subsidiaries. Responsible for Operations in the Medical Segment.
- Jutta Ludwig:
- Role: Member of the Executive Board (until Dec 31, 2024).
- Profile: Responsible for Asia Business. Stepped down at the end of 2024 and joined the Supervisory Board.
Supervisory Board (Aufsichtsrat)
- Dr. Andreas Eckert: Chairman. Founder of the company.
- Prof. Dr. Helmut Grothe: Deputy Chairman. Lawyer and University Professor.
- Paola Eckert-Palvarini: Member. Physicist.
- Dr. Edgar Löffler: Member. Medical Physicist.
- Albert Rupprecht: Member. Economist and Member of the German Bundestag.
- Jutta Ludwig: Member (since Jan 1, 2025). Economist and Sinologist.
Subsidiaries, Associates, Joint Ventures
Eckert & Ziegler SE consolidates 37 companies in its financial statements. The following are key operating entities:
Top Revenue Generating Entities:
- Eckert & Ziegler Isotope Products Inc. (USA):
- Ownership: 100%
- Role: Major revenue driver for the Isotope Products segment in North America.
- Eckert & Ziegler Radiopharma GmbH (Germany):
- Ownership: 100%
- Role: Core entity for the Medical segment, producing GalliaPharm® and offering CMO services.
- Eckert & Ziegler Isotope Products GmbH (Germany):
- Ownership: 100%
- Role: European hub for industrial and scientific sources.
- Tecnonuclear S.A. (Argentina):
- Ownership: 100%
- Role: Manufacturer of Tc-99m generators and radiopharmaceuticals for the Latin American market.
- Eckert & Ziegler Radiopharma Inc. (USA):
- Ownership: 100%
- Role: US-based radiopharmaceutical operations.
Other Significant Entities:
- Isotope Technologies Dresden GmbH: Plant engineering and hot cell manufacturing.
- Eckert & Ziegler Analytics Inc. (USA): Calibration standards.
- Eckert & Ziegler Cesio s.r.o. (Czech Republic): Production of isotopes including Ac-225.
- Qi Kang Medical Technology Co., Ltd. (China): Joint Venture (50% ownership) focusing on the Chinese market.
Physical Properties (Offices, Plants, Factories)
Eckert & Ziegler operates a global network of production sites and sales offices.
Major Production Sites:
- Berlin-Buch, Germany: The group headquarters and main production site for medical products. Features GMP clean rooms and extensive radiochemical laboratories.
- Braunschweig, Germany: A key site for the Isotope Products segment and environmental services.
- Dresden-Rossendorf, Germany: A newly inaugurated 1,700 sqm facility in 2024 dedicated to radiopharmaceutical plant engineering.
- Wilmington, Massachusetts, USA: A major production hub for bulk isotopes like Yttrium-90 and contract manufacturing.
- Valencia, California, USA: The primary manufacturing facility for industrial and scientific radiation sources.
- Buenos Aires, Argentina: Production plant for Technetium-99m generators.
- Prague (Rez), Czech Republic: Location of the new Actinium-225 production facility operated in cooperation with UJF.
- Jintan, China: A new production facility completed in 2024, set to commence radiopharmaceutical production in 2027.
Segment-wise Performance
Medical Segment
- Revenue Growth: +29% (from €115.2 million in 2023 to €148.4 million in 2024).
- EBIT Growth: Adjusted EBIT increased by €14.4 million to €39.7 million.
- Drivers: Strong demand for radiopharmaceuticals, expansion of CMO services, and sales of plant engineering equipment.
- Issues: An impairment loss of €4.8 million was recognized due to a supplier (Atom Mines LLC) falling short of expectations for Ytterbium production.
Isotope Products Segment
- Revenue Growth: +13% (from €130.9 million in 2023 to €147.5 million in 2024).
- EBIT Growth: Adjusted EBIT increased to €31.0 million (2023: €24.3 million).
- Drivers: Robust demand for industrial sources and energy sector exploration tools. Price adjustments also contributed to margin improvement.
- Issues: Negative currency effects from the hyperinflationary environment in Argentina impacted earnings by €2.1 million.
Founders
Dr. Andreas Eckert
Dr. Andreas Eckert founded the company in 1992. He served as the CEO for many years, steering the company from a small startup to a global leader in isotope technology. He is currently the Chairman of the Supervisory Board and remains the largest shareholder. His vision has been instrumental in the company’s focus on radiopharmaceuticals and its expansion into international markets.
Shareholding Pattern
As of December 31, 2024, the share capital was divided into 21,171,932 bearer shares.
- Principal Shareholder:
- Dr. Andreas Eckert (via Eckert Wagniskapital und Frühphasenfinanzierung GmbH): Holds approximately 31.16% of the shares.
- Free Float: Approximately 68.84% is held by institutional and private investors.
- Treasury Shares: The company held 326,234 treasury shares (1.5% of share capital) as of the reporting date.
Parent
Eckert & Ziegler SE acts as the parent company for the group. It is not a subsidiary of another corporation but is significantly influenced by its founder, Dr. Andreas Eckert, through his investment vehicle Eckert Wagniskapital und Frühphasenfinanzierung GmbH.
Investments and Capital Expenditure Plans
- Capital Expenditure (2024): €17.2 million invested in intangible assets and property, plant, and equipment.
- Focus Areas:
- Dresden: Expansion of the production site for plant engineering (investment up to €50 million planned over time).
- Prague: Investment in the Actinium-225 production facility.
- Wilmington (USA): Expansion of production capacities for Lutetium-177.
- Jintan (China): Completion of the first phase of the new production building.
- R&D Strategy: Research and development expenses for continuing operations were €4.8 million. The focus is on optimizing production processes for isotopes like Ac-225 and developing customized automation solutions for radiopharmaceutical synthesis.
Future Strategy
Eckert & Ziegler’s strategy is focused on capitalizing on the rapid growth of the radiopharmaceutical market, particularly in “Theranostics” (combined therapy and diagnostics).
- Expansion of Isotope Capacities: The company plans to scale up the production of Actinium-225 to meet expected global shortages. GMP-grade Ac-225 is expected to be introduced to the market in the first half of 2025.
- Global CMO Services: Expanding contract manufacturing capabilities in Europe, the US, and eventually China to support pharmaceutical companies from clinical trials to commercial launch.
- Regional Expansion: Increasing market penetration in Asia through the new Chinese facility and expanding GalliaPharm® availability in Japan.
- Forecast 2025: The management forecasts revenue of approximately €320 million and an adjusted EBIT of around €78 million for the 2025 financial year.
Key Strengths
- Integrated Business Model: Eckert & Ziegler controls the entire value chain from isotope production to equipment manufacturing and logistics.
- Global Infrastructure: A network of GMP-certified sites in Europe and the USA allows for reliable supply to global pharma customers.
- Regulatory Expertise: Decades of experience in managing complex radioactive licenses and approvals (FDA, EMA, etc.) creates a high barrier to entry for competitors.
- Diversified Portfolio: A balanced revenue stream between the high-growth Medical segment and the stable, cash-generating Isotope Products segment.
- Financial Health: A strong equity ratio of 50% and a net financial position of €98 million provide resilience and firepower for investments.
Key Challenges and Risks
- Regulatory Risks: Operations are subject to strict government supervision. The withdrawal or non-renewal of handling licenses (e.g., ongoing litigation regarding the Braunschweig site) could impact operations.
- Disposal Obligations: The company holds significant provisions (€82.8 million non-current) for the disposal of radioactive waste. Rising external disposal costs or regulatory changes could exceed these provisions.
- Geopolitical Risks: The war in Ukraine poses procurement risks for raw isotopes from Russia. While deliveries continued in 2024, future sanctions or logistical barriers remain a threat.
- IT Security: The company’s IT infrastructure was subject to a cyberattack in February 2025. While business continued, this highlights the operational risk of digital threats.
- Raw Material Dependency: Dependence on specific reactors or suppliers for raw isotopes (e.g., Ytterbium, Radium-226) could lead to supply bottlenecks.
Conclusion and Strategic Outlook
Eckert & Ziegler SE has successfully transformed itself in 2024, streamlining its structure through the SE conversion and the spin-off of its clinical drug development arm. The company is now purely focused on its core competency: being a premium supplier of isotopes and technology to the medical and industrial sectors.
With the radiopharmaceutical market poised for exponential growth, particularly in targeted alpha therapies, Eckert & Ziegler’s timely investment in Actinium-225 production positions it as a key infrastructure player. The company’s record financial results in 2024 demonstrate the effectiveness of its strategy. Moving forward into 2025, the company is well-capitalized and strategically aligned to leverage the “Theranostics” boom, offering a compelling mix of growth potential in its Medical segment and stability in its Industrial segment.
FAQ
1. What does Eckert & Ziegler SE do?
Eckert & Ziegler SE is a manufacturer of isotope technology components. It produces radioactive isotopes for cancer therapy and diagnosis, calibration standards for scientific measurement, and radiation sources for industrial use.
2. Is Eckert & Ziegler a pharmaceutical company?
Not primarily. While it produces pharmaceutical-grade radioisotopes (precursors), it positions itself as a supplier and contract manufacturer (CMO) to the pharmaceutical industry rather than a drug developer. Its drug development arm, Pentixapharm, was spun off in 2024.
3. What is the stock ticker for Eckert & Ziegler?
The company is listed on the Frankfurt Stock Exchange with the ticker symbol EUZ.
4. What was the revenue of Eckert & Ziegler in 2024?
In the 2024 fiscal year, the company generated a total revenue of €295.8 million.
5. Does Eckert & Ziegler pay a dividend?
Yes, for the 2024 financial year, the Executive Board has proposed a dividend of €0.50 per share.
6. What are the main growth drivers for the company?
The primary growth driver is the Medical segment, specifically the demand for therapeutic radioisotopes like Lutetium-177 and Actinium-225, as well as the GalliaPharm® generator for diagnostics.
7. Where is Eckert & Ziegler located?
The headquarters are in Berlin, Germany. The company has major production sites in the USA (Wilmington, Valencia), Germany (Berlin, Braunschweig, Dresden), Argentina, and the Czech Republic.
8. What is the Pentixapharm spin-off?
In October 2024, Eckert & Ziegler spun off its clinical drug development division, Pentixapharm AG, into a separate listed company. This was done to separate the capital-intensive drug development business from the profitable core isotope business.
Official Site: https://www.ezag.com
Source: Content on FirmsWorld.com is based on publicly available corporate filings, regulatory disclosures, annual reports, SEC 10-K filings, investor relations materials, and, where applicable, direct communications with the company.
